These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7809150)

  • 41. Morphologic and biochemical studies of canine mucopolysaccharidosis I.
    Shull RM; Helman RG; Spellacy E; Constantopoulos G; Munger RJ; Neufeld EF
    Am J Pathol; 1984 Mar; 114(3):487-95. PubMed ID: 6320652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention of neuropathology in the mouse model of Hurler syndrome.
    Desmaris N; Verot L; Puech JP; Caillaud C; Vanier MT; Heard JM
    Ann Neurol; 2004 Jul; 56(1):68-76. PubMed ID: 15236403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial.
    Giugliani R; Giugliani L; de Oliveira Poswar F; Donis KC; Corte AD; Schmidt M; Boado RJ; Nestrasil I; Nguyen C; Chen S; Pardridge WM
    Orphanet J Rare Dis; 2018 Jul; 13(1):110. PubMed ID: 29976218
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Open issues in Mucopolysaccharidosis type I-Hurler.
    Parini R; Deodato F; Di Rocco M; Lanino E; Locatelli F; Messina C; Rovelli A; Scarpa M
    Orphanet J Rare Dis; 2017 Jun; 12(1):112. PubMed ID: 28619065
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene therapy of the brain in the dog model of Hurler's syndrome.
    Ciron C; Desmaris N; Colle MA; Raoul S; Joussemet B; Vérot L; Ausseil J; Froissart R; Roux F; Chérel Y; Ferry N; Lajat Y; Schwartz B; Vanier MT; Maire I; Tardieu M; Moullier P; Heard JM
    Ann Neurol; 2006 Aug; 60(2):204-13. PubMed ID: 16718701
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Hurler syndrome. Early diagnosis and successful enzyme replacement therapy: a new therapeutic approach. Case report].
    Dupont C; El Hachem C; Harchaoui S; Ribault V; Amiour M; Guillot M; Maire I; Froissart R; Guffon-Fouilhoux N
    Arch Pediatr; 2008 Jan; 15(1):45-9. PubMed ID: 18162380
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Penetration, diffusion, and uptake of recombinant human alpha-L-iduronidase after intraventricular injection into the rat brain.
    Belichenko PV; Dickson PI; Passage M; Jungles S; Mobley WC; Kakkis ED
    Mol Genet Metab; 2005; 86(1-2):141-9. PubMed ID: 16006167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mucopolysaccharidosis type I.
    Wraith JE; Jones S
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune response hinders therapy for lysosomal storage diseases.
    Ponder KP
    J Clin Invest; 2008 Aug; 118(8):2686-9. PubMed ID: 18654672
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mixed donor chimerism and low level iduronidase expression may be adequate for neurodevelopmental protection in Hurler Syndrome.
    Conway J; Dyack S; Crooks BN; Fernandez CV
    J Pediatr; 2005 Jul; 147(1):106-8. PubMed ID: 16027706
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Encapsulated engineered myoblasts can cure Hurler syndrome: preclinical experiments in the mouse model.
    Piller Puicher E; Tomanin R; Salvalaio M; Friso A; Hortelano G; Marin O; Scarpa M
    Gene Ther; 2012 Apr; 19(4):355-64. PubMed ID: 21716300
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Laronidase treatment of mucopolysaccharidosis I.
    Wraith EJ; Hopwood JJ; Fuller M; Meikle PJ; Brooks DA
    BioDrugs; 2005; 19(1):1-7. PubMed ID: 15691212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Craniofacial abnormalities in a murine knock-out model of mucopolysaccharidosis I H: a computed tomography and anatomic study.
    Graupman P; Pan D; Konair B; Hartung S; McIvor S; Whitley C; Low W; Lam CH
    J Craniofac Surg; 2004 May; 15(3):392-8. PubMed ID: 15111796
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
    Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
    Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Arterial pathology in canine mucopolysaccharidosis-I and response to therapy.
    Lyons JA; Dickson PI; Wall JS; Passage MB; Ellinwood NM; Kakkis ED; McEntee MF
    Lab Invest; 2011 May; 91(5):665-74. PubMed ID: 21383673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The defect in the Hurler and Scheie syndromes: deficiency of -L-iduronidase.
    Bach G; Friedman R; Weissmann B; Neufeld EF
    Proc Natl Acad Sci U S A; 1972 Aug; 69(8):2048-51. PubMed ID: 4262258
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I.
    Pardridge WM; Boado RJ; Giugliani R; Schmidt M
    BioDrugs; 2018 Apr; 32(2):169-176. PubMed ID: 29442294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
    Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
    Mol Pharm; 2011 Aug; 8(4):1342-50. PubMed ID: 21667973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Use of 4-methylumbelliferryl-alpha-L-iduronide and 4-trifluoromethylumbelliferryl-alpha-L-iduronide for detecting alpha-L-iduronidase deficiencies in human tissue and for rapid prenatal diagnosis of Hurler disease].
    Tsvetkova IV; Karpova EA; Voznyĭ IaV; Zolotukhina TV; Biriukov VB; Semiachkina AN
    Vopr Med Khim; 1991; 37(1):74-7. PubMed ID: 1907053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.
    Dickson PI; Kaitila I; Harmatz P; Mlikotic A; Chen AH; Victoroff A; Passage MB; Madden J; Le SQ; Naylor DE;
    Mol Genet Metab; 2015; 116(1-2):69-74. PubMed ID: 26260077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.